Percentage of patients with no new lesions during the double blind period (intent-to-treat population)
| Proportion of patients free from new lesions, n (%) | |||
|---|---|---|---|
| Variable | Subcutaneous IFN β-1a three times a week (n=171) | Subcutaneous IFN β-1a once a week (n=175) | Placebo (n=171) |
| New T2 lesions | 65 (40.1) | 46 (27.4) | 32 (19.8) |
| New T1 hypointense lesions | 67 (41.4) | 45 (26.8) | 40 (24.7) |
| New Gd+ lesions | 120 (74.1) | 84 (50.0) | 49 (30.2) |
| New Gd+ or new T2 lesions | 59 (36.4) | 37 (22.0) | 24 (14.8) |
Gd+, gadolinium-enhancing; IFN, interferon.